bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S3 from Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Authors: Soumerai Tara E. , Donoghue Mark T.A. , Bandlamudi Chaitanya , Srinivasan Preethi , Chang Matthew T. , Zamarin Dmitriy , Cadoo Karen A. , Grisham Rachel N. , O'Cearbhaill Roisin E. , Tew William P. , Konner Jason A. , Hensley Martee L. , Makker Vicky , Sabbatini Paul , Spriggs David R. , Troso-Sandoval Tiffany A. , Charen Alexandra Snyder , Friedman Claire , Gorsky Mila , Schweber Sarah J. , Middha Sumit , Murali Rajmohan , Chiang Sarah , Park Kay J. , Soslow Robert A. , Ladanyi Marc , Li Bob T. , Mueller Jennifer , Weigelt Britta , Zehir Ahmet , Berger Michael F. , Abu-Rustum Nadeem R. , Aghajanian Carol , DeLair Deborah F. , Solit David B. , Taylor Barry S. , Hyman David M.
Published: April 2023

Mutation cancer cell fraction (CCF) comparisons between matched pairs of primary tumor and metastasis
Figure S3 from Metformin Inhibits Prostate Cancer Progression by Targeting Tumor-Associated Inflammatory Infiltration
Authors: Liu Qiuli , Tong Dali , Liu Gaolei , Gao Jie , Wang Lin-ang , Xu Jing , Yang Xingxia , Xie Qiubo , Huang Yiqiang , Pang Jian , Wang Luofu , He Yong , Zhang Dianzheng , Ma Qiang , Lan Weihua , Jiang Jun
Published: April 2023

Supplementary Figure S3. The effects of macrophages and metformin on tumor cell invasion and migration. (A) Illustration of PCa invasion and migration with macrophage co-culture in vitro model. The PCa cells were plated into lower 24-well plates, while the macrophage cells were plated in the upper chambers. The co-culture system was treated with/without metformin (20 mM) for 48 h. The CM was collected, diluted with 10% fresh FBS medium (1:1), and then put into the lower 24-well plates. The parental PCa cells were then placed in the upper chamber of transwell plates with/without Matrigel pre-coated inserts in serum-free medium for the invasion/migration assay. (B and C) The LNCaP (B) and RM-1 (C) cells that invaded/migrated to the corresponding CM were stained with crystal violet and five randomly selected views (Magnifications: 40Ã-) were counted. * p < 0.05.
Figure S6 from A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Iizuka Akira , Nonomura Chizu , Ashizawa Tadashi , Kondou Ryota , Ohshima Keiichi , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Akiyama Yasuto
Published: April 2023

B7-H4 staining of an array with various human normal and tumor tissues
Figure S4 from A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Iizuka Akira , Nonomura Chizu , Ashizawa Tadashi , Kondou Ryota , Ohshima Keiichi , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Akiyama Yasuto
Published: April 2023

In vivo imaging and pharmacokinetic study of Cy5.5-labeled anti-B7-H4 BsAb (Fab-scFv)
Table S1 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S1
Supplemental Table 2 from Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials
Authors: Chumsri Saranya , Serie Daniel J. , Li Zhuo , Pogue-Geile Katherine L. , Soyano-Muller Aixa E. , Mashadi-Hossein Afshin , Warren Sarah , Lou Yanyan , Colon-Otero Gerardo , Knutson Keith L. , Perez Edith A. , Moreno-Aspitia Alvaro , Thompson E. Aubrey
Published: April 2023

Supplemental Table 2
Supplementary Data-clean from Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study
Authors: Morgensztern Daniel , Besse Benjamin , Greillier Laurent , Santana-Davila Rafael , Ready Neal , Hann Christine L. , Glisson Bonnie S. , Farago Anna F. , Dowlati Afshin , Rudin Charles M. , Le Moulec Sylvestre , Lally Satwant , Yalamanchili Sreeni , Wolf Jürgen , Govindan Ramaswamy , Carbone David P.
Published: April 2023

Supplementary Table S1: Efficacy by investigator assessment. Supplementary Table S2: Objective response rate by Central Radiographic Assessment in key subgroups of interest. Supplementary Table S3: Efficacy in 3L patients by Central Radiographic Assessment. Supplementary Table S4: Deaths attributable to drug-related, treatment-emergent adverse events (TEAEs). Supplementary Table S5. Overview of pleural effusions. Supplementary Table S6. Overview of pericardial effusions. Supplementary Table S7. Overview of edema. Supplementary Table S8: Overview of cutaneous reactions.
Table S1 from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Authors: Balakrishnan Ashwini , Rajan Anusha , Salter Alexander I. , Kosasih Paula L. , Wu Qian , Voutsinas Jenna , Jensen Michael C. , Plückthun Andreas , Riddell Stanley R.
Published: April 2023

TABLE S1: 9-mer peptides in the scFv and DARPin sequences with predicted binding to the MHC class I supertype with a predicted binding affinity of less than 100 nM
Figure S1 from Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors
Authors: Balakrishnan Ashwini , Rajan Anusha , Salter Alexander I. , Kosasih Paula L. , Wu Qian , Voutsinas Jenna , Jensen Michael C. , Plückthun Andreas , Riddell Stanley R.
Published: April 2023

FIGURE S1: Design and testing of E01 DARPin CAR
Supplementary Data from The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma
Authors: Kim Sun-Hee , Roszik Jason , Cho Sung-Nam , Ogata Dai , Milton Denái R. , Peng Weiyi , Menter David G. , Ekmekcioglu Suhendan , Grimm Elizabeth A.
Published: April 2023

Supplementary Figure 1. Gating strategies for flow cytometry data analysis. Supplementary Figure 2. Co-staining of mPGES1 and S100 in human melanoma tissues. Supplementary Figure 3. Chemokines/cytokines related to COX2 or mPGES1 in melanoma. Supplementary Figure 4. Effect of COX2 or mPGES1 inhibitors on surface expression of PD-L1. Supplementary Figure 5. Comparison of PGE2 level and cell viability in scramble, PTGES KO and PTGS1/PTGS2 double KO mouse melanoma cell lines. Supplementary Figure 6. Prognostic effect of mPGES1 in Stage IV melanoma. Supplementary Figure 7. Association between mPGES1 levels and response of anti-PD-1 therapy.
Table S3 from Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Authors: Gray Jhanelle E. , Okamoto Isamu , Sriuranpong Virote , Vansteenkiste Johan , Imamura Fumio , Lee Jong Seok , Pang Yong-Kek , Cobo Manuel , Kasahara Kazuo , Cheng Ying , Nogami Naoyuki , Cho Eun Kyung , Su Wu Chou , Zhang Guili , Huang Xiangning , Li-Sucholeiki Xiaocheng , Lentrichia Brian , Dearden Simon , Jenkins Suzanne , Saggese Matilde , Rukazenkov Yuri , Ramalingam Suresh S.
Published: April 2023

Table S3 shows the numbers of patients with discordant EGFR mutation test results
Figure S1 from Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer
Authors: Corredor Germán , Wang Xiangxue , Zhou Yu , Lu Cheng , Fu Pingfu , Syrigos Konstantinos , Rimm David L. , Yang Michael , Romero Eduardo , Schalper Kurt A. , Velcheti Vamsidhar , Madabhushi Anant
Published: April 2023

Figure S1. Patient selection workflow for the datasets included in this study.
Supplementary Legend from First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Authors: Allen Bryan G. , Bodeker Kellie L. , Smith Mark C. , Monga Varun , Sandhu Sonia , Hohl Raymond , Carlisle Thomas , Brown Heather , Hollenbeck Nancy , Vollstedt Sandy , Greenlee Jeremy D. , Howard Matthew A. , Mapuskar Kranti A. , Seyedin Steven N. , Caster Joseph M. , Jones Karra A. , Cullen Joseph J. , Berg Daniel , Wagner Brett A. , Buettner Garry R. , TenNapel Mindi J. , Smith Brian J. , Spitz Douglas R. , Buatti John M.
Published: April 2023

Supplementary Legend
Supplementary Data from Whole–Genome Sequencing of Childhood Cancer Survivors Treated with Cranial Radiation Therapy Identifies 5p15.33 Locus for Stroke: A Report from the St. Jude Lifetime Cohort Study
Authors: Sapkota Yadav , Cheung Yin Ting , Moon Wonjong , Shelton Kyla , Wilson Carmen L. , Wang Zhaoming , Mulrooney Daniel A. , Zhang Jinghui , Armstrong Gregory T. , Hudson Melissa M. , Robison Leslie L. , Krull Kevin R. , Yasui Yutaka
Published: April 2023

Supplementary Data clean
Figure S3 from Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization
Authors: Schirripa Marta , Biason Paola , Lonardi Sara , Pella Nicoletta , Pino Maria Simona , Urbano Federica , Antoniotti Carlotta , Cremolini Chiara , Corallo Salvatore , Pietrantonio Filippo , Gelsomino Fabio , Cascinu Stefano , Orlandi Armando , Munari Giada , Malapelle Umberto , Saggio Serena , Fontanini Gabriella , Rugge Massimo , Mescoli Claudia , Lazzi Stefano , Reggiani Bonetti Luca , Lanza Giovanni , Dei Tos Angelo Paolo , De Maglio Giovanna , Martini Maurizio , Bergamo Francesca , Zagonel Vittorina , Loupakis Fotios , Fassan Matteo
Published: April 2023

Supplementary Figure S3
Supplementary Tables from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Tables S1-4
Supplementary table 1 from PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial
Authors: Kitson Sarah J. , Maskell Zoe , Sivalingam Vanitha N. , Allen Jennifer L. , Ali Saad , Burns Sean , Gilmour Kyle , Latheef Rahamatulla , Slade Richard J. , Pemberton Philip W. , Shaw Joseph , Ryder W. David , Kitchener Henry C. , Crosbie Emma J.
Published: April 2023

Immunohistochemistry staining protocols
Figure S5 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S5
Figure S2 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S2
Figure S1 from Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia
Authors: Del Papa Beatrice , Baldoni Stefano , Dorillo Erica , De Falco Filomena , Rompietti Chiara , Cecchini Debora , Cantelmi Maria Grazia , Sorcini Daniele , Nogarotto Manuel , Adamo Francesco Maria , Mezzasoma Federica , Silva Barcelos Estevão Carlos , Albi Elisa , Iacucci Ostini Roberta , Di Tommaso Ambra , Marra Andrea , Montanaro Guido , Martelli Maria Paola , Falzetti Franca , Di Ianni Mauro , Rosati Emanuela , Sportoletti Paolo
Published: April 2023

Figure S1
Supplementary Methods from Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma
Authors: Eberle-Singh Jaime A. , Sagalovskiy Irina , Maurer H. Carlo , Sastra Stephen A. , Palermo Carmine F. , Decker Amanda R. , Kim Min Jung , Sheedy Josephine , Mollin Anna , Cao Liangxian , Hu Jianhua , Branstrom Arthur , Weetall Marla , Olive Kenneth P.
Published: April 2023

Supplementary Methods
Supplementary Figures 1 - 7 from Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma
Authors: Eberle-Singh Jaime A. , Sagalovskiy Irina , Maurer H. Carlo , Sastra Stephen A. , Palermo Carmine F. , Decker Amanda R. , Kim Min Jung , Sheedy Josephine , Mollin Anna , Cao Liangxian , Hu Jianhua , Branstrom Arthur , Weetall Marla , Olive Kenneth P.
Published: April 2023

Supplementary Figures 1 - 7
Supplementary Figures from Circulating Tumor DNA Profiling in Small-Cell Lung Cancer Identifies Potentially Targetable Alterations
Authors: Devarakonda Siddhartha , Sankararaman Sumithra , Herzog Brett H. , Gold Kathryn A. , Waqar Saiama N. , Ward Jeffrey P. , Raymond Victoria M. , Lanman Richard B. , Chaudhuri Aadel A. , Owonikoko Taofeek K. , Li Bob T. , Poirier John T. , Rudin Charles M. , Govindan Ramaswamy , Morgensztern Daniel
Published: April 2023

Supplementary figures 1-6
Supplementary Data from Targeting Glutamine Metabolism and Redox State for Leukemia Therapy
Authors: Gregory Mark A. , Nemkov Travis , Park Hae J. , Zaberezhnyy Vadym , Gehrke Sarah , Adane Biniam , Jordan Craig T. , Hansen Kirk C. , D’Alessandro Angelo , DeGregori James
Published: April 2023

Figure S1. The glutaminase inhibitor CB-839 impairs glutathione metabolism in FLT3WT AML cells. Figure S2. The glutaminase inhibitor CB-839 decreases glutathione levels, but does not increase total cellular ROS levels in AML cells. Figure S3. Antioxidant vitamin E suppresses mitoROS and apoptosis induced by CB-839/pro-oxidant combination therapies. Figure S4. CB-839 cooperates with the pro-oxidant drug ATO in inducing apoptosis, mitoROS and AML cell death. Figure S5. CB-839/HHT therapy induces total cellular ROS. AML cells that survive therapy are metabolically similar to drug naive cells and are not resistant to subsequent therapy. Figure S6. CB-839/ATO and CB-839/HHT combination therapies do not exhibit toxicity in vivo in mice or toward normal human CD34+ cells. Figure S7. CB-839 cooperates with HHT in inducing mitoROS and apoptosis in primary human AML cells and cell death/apoptosis in ALL cells. Table S1. Combination index (CI values) for drug combinations tested in cell viability assays. Table S2. The clinical characteristics of the AML cohort studied are summarized.
Supplementary methods from Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks
Authors: Sundaravel Sriram , Kuo Wen-Liang , Jeong Jong Jin , Choudhary Gaurav S. , Gordon-Mitchell Shanisha , Liu Hui , Bhagat Tushar D. , McGraw Kathy L. , Gurbuxani Sandeep , List Alan F. , Verma Amit , Wickrema Amittha
Published: April 2023

Supplementary methods
Supplementary Table S9 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S9
Supplementary Data from A Novel ACKR2-Dependent Role of Fibroblast-Derived CXCL14 in Epithelial-to-Mesenchymal Transition and Metastasis of Breast Cancer
Authors: Sjöberg Elin , Meyrath Max , Milde Laura , Herrera Mercedes , Lövrot John , Hägerstrand Daniel , Frings Oliver , Bartish Margarita , Rolny Charlotte , Sonnhammer Erik , Chevigné Andy , Augsten Martin , Östman Arne
Published: April 2023

FIGURES. Fig S1, Bioinformatics reveal potential CXCL14-receptor candidates; Fig. S2, Expression of CXCL14 correlates with EMT in breast cancer patients; Fig. S3, Expression of CXCL14 correlates with EMT in breast, prostate and ovarian cancer patients; Fig. S4, Enhanced expression of CXCL14 and ACKR2 correlates with EMT in ovarian and prostate cancer patients; Fig. S5, CXCL14-fibroblasts stimulate the EMT program in xenograft tumors; Fig. S6, Soluble factors secreted by CXCL14-fibroblasts induce EMT of breast cancer cells in vitro; Fig. S7, CXCL14-fibroblasts enhance invasion of breast cancer cells; Fig. S8, CXCL14-responsive and non-responsive breast cancer cell lines; Fig. S9, CXCL14 signals through a Gαi-coupled receptor; Fig. S10, CXCL14 responses depend on ACKR2; Fig. S11, Downregulation of ACKR2 abolishes CXCL14-induced ERK signaling; Fig. S12, CXCL14 is not a direct ligand of ACKR2; Fig. S13, Correlation of CXCL14 expression levels and EMT does not reflect stroma abundance; Fig. S14, Enhanced expression of CXCL14 and ACKR2 predicts worse outcome in breast cancer patients; Fig. S15, Identification of potential mediators of CXCL14-fibroblast- stimulated breast cancer EMT; Fig. S16, A CXCL14-ACKR2-NOS1 axis in fibroblasts stimulates EMT and invasion of breast cancer cells // TABLES. Table S1, Primers for the amplification of human and murine genes by qRT-PCR; Table S2, Scored levels of E-Cadherin and CytK8/18 in MCF7 breast xenograft tumors, and CytK8/18 in LnCaP prostate xenograft tumors; Table S3, CXCL14 candidate receptor expression in CXCL14-responsive and non-responsive cell lines; Table S4, Multivariable analysis for CXCL14high/ACKR2high subgroup of breast cancer patients from the TCGA gene expression dataset; Table S5, Univariable cox-regression analyses for the CXCL14 (high)/ACKR2(high) subgroup (90-percentile) in publicly available gene expression datasets (TCGA) from 13 different tumor types.
Supplementary Table S4 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S4
Supplementary Table S2 from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Table S2
Supplementary Data from Therapeutic Targeting of Non-oncogene Dependencies in High-risk Neuroblastoma
Authors: Huang Chen-Tsung , Hsieh Chiao-Hui , Lee Wen-Chi , Liu Yen-Lin , Yang Tsai-Shan , Hsu Wen-Ming , Oyang Yen-Jen , Huang Hsuan-Cheng , Juan Hsueh-Fen
Published: April 2023

Supplementary Figures and Supplementary Table captions
Supplementary Legend from Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC)
Authors: Chen Kezhong , Zhao Heng , Shi Yanbin , Yang Fan , Wang Lien Tu , Kang Guannan , Nie Yuntao , Wang Jun
Published: April 2023

Supplementary Legend
Supplementary Material from Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer
Authors: Salem Ahmed , Little Ross A. , Latif Ayşe , Featherstone Adam K. , Babur Muhammad , Peset Isabel , Cheung Susan , Watson Yvonne , Tessyman Victoria , Mistry Hitesh , Ashton Garry , Behan Caron , Matthews Julian C. , Asselin Marie-Claude , Bristow Robert G. , Jackson Alan , Parker Geoff J.M. , Faivre-Finn Corinne , Williams Kaye J. , O'Connor James P.B.
Published: April 2023

Supplementary Material
Supplementary Figure 1 from Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin
Authors: Lee Dae-Won , Han Sae-Won , Bae Jeong Mo , Jang Hoon , Han Hyojun , Kim Hyoki , Bang Duhee , Jeong Seung-Yong , Park Kyu Joo , Kang Gyeong Hoon , Kim Tae-You
Published: April 2023

Prognostic role of tumor mutation burden (TMB) stratified by microsatellite instability (MSI) status.
Supplementary Video S7 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Video S7. Time-lapse images of hTERT-RPE1-Arl13b-GFP cells starved in serum-free Opti-MEM for 48 hours, then incubated for 3 hours in 2.5 µM erlotinib + 20% FBS.
Supplementary Video S5 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Video S5. Time-lapse images of hTERT-RPE1-Arl13b-GFP cells starved in serum-free Opti-MEM for 48 hours, then incubated for 3 hours in 2.5 µM sunitinib.
Supplementary Video S3 from Unexpected Activities in Regulating Ciliation Contribute to Off-target Effects of Targeted Drugs
Authors: Kiseleva Anna A. , Korobeynikov Vladislav A. , Nikonova Anna S. , Zhang Peishan , Makhov Petr , Deneka Alexander Y. , Einarson Margret B. , Serebriiskii Ilya G. , Liu Hanqing , Peterson Jeffrey R. , Golemis Erica A.
Published: April 2023

Supplementary Video S3. Time-lapse images of hTERT-RPE1-Arl13b-GFP cells starved in serum-free Opti-MEM for 48 hours, then incubated for 3 hours in 1 µM alisertib + 20% FBS.
Supplementary Data from Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma
Authors: Cassaday Ryan D. , Press Oliver W. , Pagel John M. , Rajendran Joseph G. , Gooley Ted A. , Fisher Darrell R. , Holmberg Leona A. , Miyaoka Robert S. , Sandmaier Brenda M. , Green Damian J. , Gopal Ajay K.
Published: April 2023

Supplementary Methods and Results
Supplementary Figure 3 from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Authors: Flaifel Abdallah , Xie Wanling , Braun David A. , Ficial Miriam , Bakouny Ziad , Nassar Amin H. , Jennings Rebecca B. , Escudier Bernard , George Daniel J. , Motzer Robert J. , Morris Michael J. , Powles Thomas , Wang Evelyn , Huang Ying , Freeman Gordon J. , Choueiri Toni K. , Signoretti Sabina
Published: April 2023

Consort Diagram
Supplementary Data from Inhibiting BRAF Oncogene–Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair
Authors: Robb Ryan , Yang Linlin , Shen Changxian , Wolfe Adam R. , Webb Amy , Zhang Xiaoli , Vedaie Marall , Saji Motoyasu , Jhiang Sissy , Ringel Matthew D. , Williams Terence M.
Published: April 2023

Supplementary Table 1. Thyroid cancer cells lines used in this study Supplementary Figure 1. AlamarBlue® proliferation assay of TPC-1 stable cell lines. Supplemental Figure 2. Assessment of MEK-ERK activation in TPC-1 BRAFV600E stable cells. Supplementary Figure 3. Pooled radiation sensitivity data from melanoma, thyroid, colorectal cell lines either with BRAFV600E mutation or not. Supplementary Figure 4. Representative photos of plates from radiation clonogenic assays showing the effects of BRAFV600E inhibition with vemurafenib (Vem) resulting in radiosensitization in thyroid cancer cells harboring a BRAFV600E mutation (8505C, BCPAP) compared to vehicle (Ctrl) treated cells. Supplementary Figure 5. Plating efficiency of various thyroid cancer cell lines during radiation clonogenic assays in the presence of vemurafenib (Vem, 100nM) or vehicle (Ctrl). Supplementary Figure 6. BRAFV600E inhibition radiosensitizes melanoma cancer cells harboring a BRAFV600E mutation. Supplementary Figure 7. BRAFV600E inhibition does not alter the recovery of IR-induced DNA damage in BRAFWT thyroid cancer cells. Supplemental Figure 8. Assessment of BRAFV600E expression and MEK-ERK activation in 293T cells. Supplemental Table 2. mRNA expression ratio of NHEJ associated genes of thyroid cancer with BRAFV600E mutation compared to BRAF wild-type (BRAF wild-type: 203 cases; BRAFV600E mutant: 288 cases). Supplementary Figure 9. Expression of XLF is sufficient to induce radioresistance. Supplementary Figure 10. Treatment of BRAF inhibitor did not lead to significant weight loss of mice.
Supplementary Figures 1-5 from Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan
Authors: Reidy-Lagunes Diane , Pandit-Taskar Neeta , O'Donoghue Joseph A. , Krebs Simone , Staton Kevin D. , Lyashchenko Serge K. , Lewis Jason S. , Raj Nitya , Gönen Mithat , Lohrmann Christian , Bodei Lisa , Weber Wolfgang A.
Published: April 2023

Supplementary Figures 1-5
Figure S1 - Detailed design of 6 AR-V567es detection approaches from Comparative Analysis of AR Variant AR-V567es mRNA Detection Systems Reveals Eminent Variability and Questions the Role as a Clinical Biomarker in Prostate Cancer
Authors: Bernemann Christof , Humberg Verena , Thielen Barbara , Steinestel Julie , Chen Xin , Duensing Stefan , Schrader Andres J. , Boegemann Martin
Published: April 2023

A) Genomic structure of the AR gene. B) Sequences of exon 4/8 spanning primers used in 6 different PCR assays (except PCR assay #4). C) PCR assay #4 (22) would lead to two distinct PCR products with the respective size, i.e. AR-V567es and AR-FL. Abbreviations: AR-FL, full length AR; bp, base pairs
Supplementary Figures 1-7 from Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell Death
Authors: Froeling Fieke E.M. , Swamynathan Manojit Mosur , Deschênes Astrid , Chio Iok In Christine , Brosnan Erin , Yao Melissa A. , Alagesan Priya , Lucito Matthew , Li Juying , Chang An-Yun , Trotman Lloyd C. , Belleau Pascal , Park Youngkyu , Rogoff Harry A. , Watson James D. , Tuveson David A.
Published: April 2023

Supplementary Figures 1,2,3,4,5,6,7
Figure S3 from The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity
Authors: Heisey Daniel A.R. , Lochmann Timothy L. , Floros Konstantinos V. , Coon Colin M. , Powell Krista M. , Jacob Sheeba , Calbert Marissa L. , Ghotra Maninderjit S. , Stein Giovanna T. , Maves Yuki Kato , Smith Steven C. , Benes Cyril H. , Leverson Joel D. , Souers Andrew J. , Boikos Sosipatros A. , Faber Anthony C.
Published: April 2023

Olaparib induces similar levels of DNA damage in CHLA9 and CHLA10
Supplementary Figure legends from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Authors: Peng Weiyi , Williams Leila J. , Xu Chunyu , Melendez Brenda , McKenzie Jodi A. , Chen Yuan , Jackson Heather L. , Voo Kui S. , Mbofung Rina M. , Leahey Sara Elizabeth , Wang Jian , Lizee Gregory , Tawbi Hussein A. , Davies Michael A. , Hoos Axel , Smothers James , Srinivasan Roopa , Paul Elaine M. , Yanamandra Niranjan , Hwu Patrick
Published: April 2023

Supplementary Figure legends
Supplementary Methods from Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
Authors: Carbajosa Sofía , Pansa María Florencia , Paviolo Natalia S. , Castellaro Andrés M. , Andino Diego L. , Nigra Ayelén D. , García Iris Alejandra , Racca Ana C. , Rodriguez-Berdini Lucía , Angiolini Virginia , Guantay Laura , Villafañez Florencia , Federico María Belén , Rodríguez-Baili María Celeste , Caputto Beatriz L. , Drewes Gerard , Madauss Kevin P. , Gloger Israel , Fernandez Elmer , Gil Germán A. , Bocco José Luis , Gottifredi Vanesa , Soria Gastón
Published: April 2023

Extended methods including bionformatic analysis details and scripts used
Figure S1 from Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma
Authors: Peng Weiyi , Williams Leila J. , Xu Chunyu , Melendez Brenda , McKenzie Jodi A. , Chen Yuan , Jackson Heather L. , Voo Kui S. , Mbofung Rina M. , Leahey Sara Elizabeth , Wang Jian , Lizee Gregory , Tawbi Hussein A. , Davies Michael A. , Hoos Axel , Smothers James , Srinivasan Roopa , Paul Elaine M. , Yanamandra Niranjan , Hwu Patrick
Published: April 2023

The expression and function of OX40 on tumor-reactive T cells
Supplementary Figure S2 from Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy
Authors: Klanova Magdalena , Oestergaard Mikkel Z. , Trněný Marek , Hiddemann Wolfgang , Marcus Robert , Sehn Laurie H. , Vitolo Umberto , Bazeos Alexandra , Goede Valentin , Zeuner Harald , Knapp Andrea , Sahin Deniz , Spielewoy Nathalie , Bolen Christopher R. , Cardona Andres , Klein Christian , Venstrom Jeffrey M. , Nielsen Tina , Fingerle-Rowson Günter
Published: April 2023

Association between baseline peripheral blood NKCC and tumor NK cell gene expression in FL (A) and DLBCL (B)
Supplementary Data from Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Authors: Ponz-Sarvise Mariano , Corbo Vincenzo , Tiriac Hervé , Engle Dannielle D. , Frese Kristopher K. , Oni Tobiloba E. , Hwang Chang-Il , Öhlund Daniel , Chio Iok In Christine , Baker Lindsey A. , Filippini Dea , Wright Kevin , Bapiro Tashinga E. , Huang Pearl , Smith Paul , Yu Kenneth H. , Jodrell Duncan I. , Park Youngkyu , Tuveson David A.
Published: April 2023

Supplementary Figures 1-3
Supplementary Tables from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary Tables
Supplementary Figure 5 from Noncanonical TGFβ Pathway Relieves the Blockade of IL1β/TGFβ-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer
Authors: Guillén Díaz-Maroto Natalia , Sanz-Pamplona Rebeca , Berdiel-Acer Mireia , Cimas Francisco J. , García Elena , Gonçalves-Ribeiro Samuel , Albert Nerea , Garcia-Vicién Gemma , Capella Gabriel , Moreno Victor , Salazar Ramon , Villanueva Alberto , Molleví David G.
Published: April 2023

Supplementary Figure 5
Table S2 from Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism
Authors: Prabhu Varun V. , Madhukar Neel S. , Gilvary Coryandar , Kline C. Leah B. , Oster Sophie , El-Deiry Wafik S. , Elemento Olivier , Doherty Faye , VanEngelenburg Alexander , Durrant Jessica , Tarapore Rohinton S. , Deacon Sean , Charter Neil , Jung Jinkyu , Park Deric M. , Gilbert Mark R. , Rusert Jessica , Wechsler-Reya Robert , Arrillaga-Romany Isabel , Batchelor Tracy T. , Wen Patrick Y. , Oster Wolfgang , Allen Joshua E.
Published: April 2023

Table S2
Supplementary Figure S4 from Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity
Authors: Current Kyle , Meyer Catherine , Magyar Clara E. , Mona Christine E. , Almajano Joel , Slavik Roger , Stuparu Andreea D. , Cheng Chloe , Dawson David W. , Radu Caius G. , Czernin Johannes , Lueckerath Katharina
Published: April 2023

PSMA expression in tumors with different fractions of PSMA-positive cells (study 2)
Supplemental Materials from Selective Progesterone Receptor Modulators in Early-Stage Breast Cancer: A Randomized, Placebo-Controlled Phase II Window-of-Opportunity Trial Using Telapristone Acetate
Authors: Lee Oukseub , Sullivan Megan E. , Xu Yanfei , Rogers Chiara , Muzzio Miguel , Helenowski Irene , Shidfar Ali , Zeng Zexian , Singhal Hari , Jovanovic Borko , Hansen Nora , Bethke Kevin P. , Gann Peter H. , Gradishar William , Kim J. Julie , Clare Susan E. , Khan Seema A.
Published: April 2023

Supplemental Materials Supplemental Table 4. Changes in serum sex hormone concentrations according to the treatments. Supplemental Table 5. Summary of BESS Quality of Life Assessment by symptom clusters according to the treatments Supplemental Table 6. Summary of Adverse Effects.
Figure S5 from IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Authors: Conlon Kevin C. , Potter E. Lake , Pittaluga Stefania , Lee Chyi-Chia Richard , Miljkovic Milos D. , Fleisher Thomas A. , Dubois Sigrid , Bryant Bonita R. , Petrus Michael , Perera Liyanage P. , Hsu Jennifer , Figg William D. , Peer Cody J. , Shih Joanna H. , Yovandich Jason L. , Creekmore Stephen P. , Roederer Mario , Waldmann Thomas A.
Published: April 2023

Supplementary Figure S5
Supplementary Data from Cancer-associated Fibroblast–promoted LncRNA DNM3OS Confers Radioresistance by Regulating DNA Damage Response in Esophageal Squamous Cell Carcinoma
Authors: Zhang Hongfang , Hua Yuhui , Jiang Zhenzhen , Yue Jing , Shi Ming , Zhen Xiaoli , Zhang Xiaoyan , Yang Ling , Zhou Rongjing , Wu Shixiu
Published: April 2023

Supplementary Figure. S7 The silence efficacy of specific siRNA in esophageal cancer cells.
Table S6 from The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents
Authors: Spriano Filippo , Chung Elaine Yee Lin , Gaudio Eugenio , Tarantelli Chiara , Cascione Luciano , Napoli Sara , Jessen Katti , Carrassa Laura , Priebe Valdemar , Sartori Giulio , Graham Garrett , Selvanathan Saravana P. , Cavalli Andrea , Rinaldi Andrea , Kwee Ivo , Testoni Monica , Genini Davide , Ye B. Hilda , Zucca Emanuele , Stathis Anastasios , Lannutti Brian , Toretsky Jeffrey A. , Bertoni Francesco
Published: April 2023

Gene expression data after TK-216 treatment (8h) in U2932. A) Supervised analysis of transcriptome after treatment B) Gene-sets significantly enriched after treatment. C) IRF4/SPIB and lenalidomide related gene-sets significantly enriched after treatment.
Table S4 from Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Authors: Alvarez Secord Angeles , Bell Burdett Kirsten , Owzar Kouros , Tritchler David , Sibley Alexander B. , Liu Yingmiao , Starr Mark D. , Brady J. Chris , Lankes Heather A. , Hurwitz Herbert I. , Mannel Robert S. , Tewari Krishnansu S. , O'Malley David M. , Gray Heidi , Bakkum-Gamez Jamie N. , Fujiwara Keiichi , Boente Matthew , Deng Wei , Burger Robert A. , Birrer Michael J. , Nixon Andrew B.
Published: April 2023

Quartile analysis of IL6. Median survival times are given in months, and HR's represent treatment hazard ratios.
Table S2 from Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Authors: Alvarez Secord Angeles , Bell Burdett Kirsten , Owzar Kouros , Tritchler David , Sibley Alexander B. , Liu Yingmiao , Starr Mark D. , Brady J. Chris , Lankes Heather A. , Hurwitz Herbert I. , Mannel Robert S. , Tewari Krishnansu S. , O'Malley David M. , Gray Heidi , Bakkum-Gamez Jamie N. , Fujiwara Keiichi , Boente Matthew , Deng Wei , Burger Robert A. , Birrer Michael J. , Nixon Andrew B.
Published: April 2023

Association between outcomes (PFS and OS) and baseline covariates (age, stage/debulking status, and performance status).
Figure S4 from Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection
Authors: Bam Rakesh , Lown Patrick S. , Stern Lawrence A. , Sharma Karina , Wilson Katheryne E. , Bean Gregory R. , Lutz Amelie M. , Paulmurugan Ramasamy , Hackel Benjamin J. , Dahl Jeremy , Abou-Elkacem Lotfi
Published: April 2023

Targeting of MB with ABYB7-H3 does not increase MB attachment to MS1WT cells.
Figure S1 from Efficacy of Affibody-Based Ultrasound Molecular Imaging of Vascular B7-H3 for Breast Cancer Detection
Authors: Bam Rakesh , Lown Patrick S. , Stern Lawrence A. , Sharma Karina , Wilson Katheryne E. , Bean Gregory R. , Lutz Amelie M. , Paulmurugan Ramasamy , Hackel Benjamin J. , Dahl Jeremy , Abou-Elkacem Lotfi
Published: April 2023

Biotinylation of ABYB7-H3.
Supplementary Figure 1F from Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG
Authors: Raut Chandrajit P. , Callegaro Dario , Miceli Rosalba , Barretta Francesco , Rutkowski Piotr , Blay Jean-Yves , Lahat Guy , Strauss Dirk C. , Gonzalez Ricardo , Ahuja Nita , Grignani Giovanni , Quagliuolo Vittorio , Stoeckle Eberhard , De Paoli Antonino , Pillarisetty Venu G. , Nessim Carolyn , Swallow Carol J. , Bagaria Sanjay , Canter Robert , Mullen John , Gelderblom Hans J. , Pennacchioli Elisabetta , van Coevorden Frits , Cardona Kenneth , Fiore Marco , Fairweather Mark , Gronchi Alessandro
Published: April 2023

Supplementary Figure 1F
Supplementary Figure 1A from Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG
Authors: Raut Chandrajit P. , Callegaro Dario , Miceli Rosalba , Barretta Francesco , Rutkowski Piotr , Blay Jean-Yves , Lahat Guy , Strauss Dirk C. , Gonzalez Ricardo , Ahuja Nita , Grignani Giovanni , Quagliuolo Vittorio , Stoeckle Eberhard , De Paoli Antonino , Pillarisetty Venu G. , Nessim Carolyn , Swallow Carol J. , Bagaria Sanjay , Canter Robert , Mullen John , Gelderblom Hans J. , Pennacchioli Elisabetta , van Coevorden Frits , Cardona Kenneth , Fiore Marco , Fairweather Mark , Gronchi Alessandro
Published: April 2023

Supplementary Figure 1A
Material and Methods from Postablation Modulation after Single High-Dose Radiation Therapy Improves Tumor Control via Enhanced Immunomodulation
Authors: Savage Talicia , Pandey Sanjay , Guha Chandan
Published: April 2023

Material and Methods
Supplementary tables 1-5 from Neoadjuvant Therapy Remodels the Pancreatic Cancer Microenvironment via Depletion of Protumorigenic Immune Cells
Authors: Mota Reyes Carmen , Teller Steffen , Muckenhuber Alexander , Konukiewitz Björn , Safak Okan , Weichert Wilko , Friess Helmut , Ceyhan Güralp O. , Demir Ihsan Ekin
Published: April 2023

Supplementary Table 1. Clinical characteristics of neoadjuvantly treated vs upfront resected PDAC patients and the types of neoadjuvant regimens. Supplementary Table 2. Specifications and dilutions of the primary antibodies used in our experimental pipeline. Supplementary Table 3. Histopathological variables used in the analysis of the PCa stroma. Supplementary Table 4. Univariate and multivariate survival analysis for prognostically relevant clinical and histological features. Supplementary Table 5. Summary of the histopathology results in the comparison of pancreatic cancer (PCa) tissues after neoadjuvant therapy (neoTx) vs. after primary resection.
Figure S2 from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary Figure
Figure S10 from Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer
Authors: Max Ma Xiaoju , Bendell Johanna C. , Hurwitz Herbert I. , Ju Christine , Lee John J. , Lovejoy Alex , Mancao Christoph , Nicholas Alan , Price Richard , Sommer Nicolas , Tikoo Nalin , Yao Lijing , Yaung Stephanie J. , Palma John F.
Published: April 2023

Supplementary Figure
Supplementary Information from Stratifin Inhibits SCFFBW7 Formation and Blocks Ubiquitination of Oncoproteins during the Course of Lung Adenocarcinogenesis
Authors: Shiba-Ishii Aya , Hong Jeongmin , Hirokawa Takatsugu , Kim Yunjung , Nakagawa Tomoki , Sakashita Shingo , Sakamoto Noriaki , Kozuma Yukinori , Sato Yukio , Noguchi Masayuki
Published: April 2023

Supplementary material and method and figure legends.
Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Authors: Reardon David A. , Desjardins Annick , Vredenburgh James J. , O'Rourke Donald M. , Tran David D. , Fink Karen L. , Nabors Louis B. , Li Gordon , Bota Daniela A. , Lukas Rimas V. , Ashby Lynn S. , Duic J. Paul , Mrugala Maciej M. , Cruickshank Scott , Vitale Laura , He Yi , Green Jennifer A. , Yellin Michael J. , Turner Christopher D. , Keler Tibor , Davis Thomas A. , Sampson John H.
Published: April 2023

Figure A1 from Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Supplementary Table S3 from Validation of the OncoMasTR Risk Score in Estrogen Receptor–Positive/HER2-Negative Patients: A TransATAC study
Authors: Buus Richard , Sestak Ivana , Barron Stephen , Loughman Tony , Fender Bozena , Ruiz Cesar Lopez , Dynoodt Peter , Wang Chan-Ju Angel , O'Leary Des , Gallagher William M. , Dowsett Mitch , Cuzick Jack
Published: April 2023

Added prognostic information to Ki67. Likelihood (Ï‡Â²) for distant recurrence for all prognostic scores in all patients and subgroups. DR, distant recurrence; OMm, OncoMasTR Molecular Score; OMclin2, OncoMasTR Risk Score.
Supplementary Tables from A Noninvasive Blood-based Combinatorial Proteomic Biomarker Assay to Detect Breast Cancer in Women over age 50 with BI-RADS 3, 4, or 5 Assessment
Authors: Henderson Meredith C. , Silver Michael , Tran Quynh , Letsios Elias E. , Mulpuri Rao , Reese David E. , Lourenco Ana P. , LaBaer Joshua , Anderson Karen S. , Alpers Josie , Costantini Carrie , Rohatgi Nitin , Ali Haythem , Baker Karen , Northfelt Donald W. , Ghosh Karthik , Grobmyer Stephen R. , Polen Winnie , Wolf Judith K.
Published: April 2023

Table S1. Enrollment Criteria Table S2. Enrollment Sites Table S3. Serum protein biomarkers (SPB) and tumor-associated autoantibodies (TAAb) evaluated in the current study. Table S4: Clinical conditions and criteria for inclusion. Table S5: Comparison of biomarker measurements between women divided by age and by FSH. Table S6: Clinical performance of Videssa Breast in all samples categorized by breast density (dense: categories a and b, non-dense: categories c and d) and by health exclusion. Table S7: Clinical performance of Videssa Breast in subjects ages 25-49.
Table S14 from Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Authors: Chakraborty Goutam , Armenia Joshua , Mazzu Ying Z. , Nandakumar Subhiksha , Stopsack Konrad H. , Atiq Mohammad O. , Komura Kazumasa , Jehane Lina , Hirani Rahim , Chadalavada Kalyani , Yoshikawa Yuki , Khan Nabeela A. , Chen Yu , Abida Wassim , Mucci Lorelei A. , Lee Gwo-Shu Mary , Nanjangud Gouri J. , Kantoff Philip W.
Published: April 2023

Supplementary Table S14
Supplementary Methods from Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma
Authors: Talhouk Aline , Derocher Heather , Schmidt Pascal , Leung Samuel , Milne Katy , Gilks C. Blake , Anglesio Michael S. , Nelson Brad H. , McAlpine Jessica N.
Published: April 2023

Supplementary Methods
Supplementary Figure 2 from Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study
Authors: Soliman Pamela T. , Westin Shannon N. , Iglesias David A. , Fellman Bryan M. , Yuan Ying , Zhang Qian , Yates Melinda S. , Broaddus Russell R. , Slomovitz Brian M. , Lu Karen H. , Coleman Robert L.
Published: April 2023

Supplementary Figure S2
Supplementary Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9 from Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Authors: Lowery Caitlin D. , Dowless Michele , Renschler Matthew , Blosser Wayne , VanWye Alle B. , Stephens Jennifer R. , Iversen Philip W. , Lin Aimee Bence , Beckmann Richard P. , Krytska Kateryna , Cole Kristina A. , Maris John M. , Hawkins Douglas S. , Rubin Brian P. , Kurmasheva Raushan T. , Houghton Peter J. , Gorlick Richard , Kolb E. Anders , Kang Min H. , Reynolds C. Patrick , Erickson Stephen W. , Teicher Beverly A. , Smith Malcolm A. , Stancato Louis F.
Published: April 2023

Supplementary Methods, Supplementary Tables 1-6, Supplementary Figures 1-9
Figure S3 from Identification of Hypermutation and Defective Mismatch Repair in ctDNA from Metastatic Prostate Cancer
Authors: Ritch Elie , Fu Simon Y.F. , Herberts Cameron , Wang Gang , Warner Evan W. , Schönlau Elena , Taavitsainen Sinja , Murtha Andrew J. , Vandekerkhove Gillian , Beja Kevin , Loktionova Yulia , Khalaf Daniel , Fazli Ladan , Kushnir Igal , Ferrario Cristiano , Hotte Sebastien , Annala Matti , Chi Kim N. , Wyatt Alexander W.
Published: April 2023

Supplementary Figure 3. Representative copy number profiles of samples harboring MSH2 and MSH6 deletions.
Figure S4 from Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer
Authors: Karasinska Joanna M. , Topham James T. , Kalloger Steve E. , Jang Gun Ho , Denroche Robert E. , Culibrk Luka , Williamson Laura M. , Wong Hui-Li , Lee Michael K.C. , O'Kane Grainne M. , Moore Richard A. , Mungall Andrew J. , Moore Malcolm J. , Warren Cassia , Metcalfe Andrew , Notta Faiyaz , Knox Jennifer J. , Gallinger Steven , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Renouf Daniel J. , Schaeffer David F.
Published: April 2023

Heatmap showing results of consensus clustering (k=2) based on expression of genes associated with normal (n=20) and active (n=22) stroma in PDAC (Moffitt et al., 2015). Robust clusters of normal (n=167) and active (n=158) stroma samples were identified. Lower heatmap shows expression values (z-score) of each gene within each sample. Metabolic subgroup is overlaid as the bottom-most track. There was no significant enrichment of any of the metabolic subgroups among the samples in active or normal stroma clusters.
Tables S2-S3 from Genomic Evolutionary Patterns of Leiomyosarcoma and Liposarcoma
Authors: Amin-Mansour Ali , George Suzanne , Sioletic Stefano , Carter Scott L. , Rosenberg Mara , Taylor-Weiner Amaro , Stewart Chip , Chevalier Aaron , Seepo Sara , Tracy Adam , Getz Gad , Hornick Jason L. , Nucci Marisa R. , Quade Bradley , Demetri George D. , Raut Chandrajit P. , Garraway Levi A. , Van Allen Eliezer M. , Wagner Andrew J.
Published: April 2023

Supplementary Tables 2 and 3
Supplementary Table 2 from Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Authors: Kandimalla Raju , Gao Feng , Matsuyama Takatoshi , Ishikawa Toshiaki , Uetake Hiroyuki , Takahashi Naoki , Yamada Yasuhide , Becerra Carlos , Kopetz Scott , Wang Xin , Goel Ajay
Published: April 2023

Supplementary Table 2: Data of miRNAs which are analyzed in the TCGA discovery cohort with associated statistical parameters.